BioAdaptives® Inc. Announces XcellaraHeart™, a Cardiovascular Wellness Formula Built on Xcellara’s Human-Clinical Data Demonstrating a 268.8% Increase in Circulating Stem ...

BioAdaptives® Inc. (OTC: BDPT), developer of the Xcellara™ line of stem cell mobilization supplements, today announced the upcoming commercial availability of XcellaraHeart™, a premium cardiovascular ...
Tech Times on MSN

PMN310 cuts Alzheimer oligomers in humans, dodging side effects that limit rival drugs

Amyloid oligomers — not plaques — may be the true neurotoxic driver of Alzheimer's disease, and ProMIS Neurosciences now has ...

Human retinas can respond to light 10 hours after death, reveals study

Scientists have kept donated human retinas responsive to light for up to 10 hours after death, marking a significant advance ...

2 Phenomenal Stocks That Could Double by 2030

If that growth materializes, there's enough upside for Circle stock to double within the next four years.